Abstract
Hypertrophic cardiomyopathy (HCM) is caused by dominant mutations in sarcomere genes. Although the diagnosis of HCM is traditionally based on identifying unexplained left ventricular hypertrophy (LVH) by cardiac imaging, LVH is not an invariable feature of disease. The expression of LVH is highly age-dependent, and LV wall thickness is typically normal during childhood. Overt cardiac hypertrophy often does not develop until adolescence or later. With genetic testing, family members who have inherited a pathogenic sarcomere mutation (G+) can be identified prior to a clinical diagnosis (LVH−). This allows characterization of a new and important subset, denoted preclinical HCM (G+/LVH−). Although there are no distinguishing morphologic features of early disease, there is evidence of myocardial dysfunction prior to the development of LVH. Otherwise healthy sarcomere mutation carriers frequently have subtle impairment of diastolic function, detectable by tissue Doppler interrogation. These findings can assist in differentiating such at-risk family members from those who did not inherit the mutation, despite the presence of normal LV wall thickness. In contrast, systolic function appears relatively preserved in preclinical HCM but impaired in overt disease, suggesting that both the sarcomere mutation and the characteristic changes in myocardial architecture (LVH, fibrosis, and disarray) are required to perturb force generation. Better characterization of preclinical HCM will identify the initial manifestations of sarcomere mutations, characterize intermediate disease phenotypes, and foster efforts to develop novel therapeutic strategies based on genetic identification of at-risk individuals and early initiation of therapy to prevent disease progression when treatment may be most effective.
Similar content being viewed by others
References
Abraham, T. P., Dimaano, V. L., & Liang, H. Y. (2007). Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation, 116, 2597–609.
Bellavia, D., Pellikka, P. A., Abraham, T. P., Al-Zahrani, G. B., Dispenzieri, A., Oh, J. K., et al. (2008). Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. American Journal of Cardiology, 101, 1039–1045.
Blanchard, E., Seidman, C., Seidman, J. G., LeWinter, M., & Maughan, D. (1999). Altered crossbridge kinetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Circulation Research, 84, 475–483.
D'Hooge, J., Heimdal, A., Jamal, F., Kukulski, T., Bijnens, B., Rademakers, F., et al. (2000). Regional strain and strain rate measurements by cardiac ultrasound: Principles, implementation and limitations. European Journal of Echocardiography, 1, 154–170.
Debold, E. P., Schmitt, J. P., Patlak, J. B., Beck, S. E., Moore, J. R., Seidman, J. G., et al. (2007). Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse alpha-cardiac myosin in the laser trap assay. American Journal of Physiology. Heart and Circulatory Physiology, 293, H284–H291.
Edvardsen, T., Gerber, B. L., Garot, J., Bluemke, D. A., Lima, J. A., & Smiseth, O. A. (2002). Quantitative assessment of intrinsic regional myocardial deformation by Doppler strain rate echocardiography in humans: Validation against three-dimensional tagged magnetic resonance imaging. Circulation, 106, 50–56.
Elliott, P., & McKenna, W. J. (2004). Hypertrophic cardiomyopathy. Lancet, 363, 1881–1891.
Fatkin, D., McConnell, B. K., Mudd, J. O., Semsarian, C., Moskowitz, I. G., Schoen, F. J., et al. (2000). An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. Journal of Clinical Investigation, 106, 1351–1359.
Geisterfer-Lowrance, A. A., Christe, M., Conner, D. A., Ingwall, J. S., Schoen, F. J., Seidman, C. E., et al. (1996). A mouse model of familial hypertrophic cardiomyopathy. Science, 272, 731–734.
Georgakopoulos, D., Christe, M. E., Giewat, M., Seidman, C. M., Seidman, J. G., & Kass, D. A. (1999). The pathogenesis of familial hypertrophic cardiomyopathy: Early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation [see comments]. Nature Medicine, 5, 327–330.
Germans, T., Wilde, A. A., Dijkmans, P. A., Chai, W., Kamp, O., Pinto, Y. M., et al. (2006). Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. Journal of the American College of Cardiology, 48, 2518–2523.
Ho, C. Y., Carlsen, C., Thune, J. J., Havndrup, O., Bundgaard, H., Farrohi, F., et al. (2009). Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circulation: Cardiovascular Genetics, 2, 314–321.
Ho, C. Y., Sweitzer, N. K., McDonough, B., Maron, B. J., Casey, S. A., Seidman, J. G., et al. (2002). Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation, 105, 2992–2997.
Koyama, J., Ray-Sequin, P. A., & Falk, R. H. (2003). Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation, 107, 2446–2452.
Maron, B. J., Seidman, J. G., & Seidman, C. E. (2004). Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 44, 2125–2132.
Mirsky, I., & Parmley, W. W. (1973). Assessment of passive elastic stiffness for isolated heart muscle and the intact heart. Circulation Research, 33, 233–243.
Moon, J. C., Mogensen, J., Elliott, P. M., Smith, G. C., Elkington, A. G., Prasad, S. K., et al. (2005). Myocardial late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy caused by mutations in troponin I. Heart, 91, 1036–1040.
Nagueh, S. F., Bachinski, L. L., Meyer, D., Hill, R., Zoghbi, W. A., Tam, J. W., et al. (2001). Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation, 104, 128–130.
Nagueh, S. F., Kopelen, H. A., Lim, D. S., Zoghbi, W. A., Quinones, M. A., Roberts, R., et al. (2000). Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation, 102, 1346–1350.
Niimura, H., Bachinski, L. L., Sangwatanaroj, S., Watkins, H., Chudley, A. E., McKenna, W., et al. (1998). Mutations in the gene for cardiac myosin-binding protein C and late- onset familial hypertrophic cardiomyopathy [see comments]. New England Journal of Medicine, 338, 1248–1257.
Richard, P., Villard, E., Charron, P., & Isnard, R. (2006). The genetic bases of cardiomyopathies. Journal of the American College of Cardiology, 48, A79–A89.
Seidman, J. G., & Seidman, C. (2001). The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell, 104, 557–567.
Semsarian, C., Ahmad, I., Giewat, M., Georgakopoulos, D., Schmitt, J. P., McConnell, B. K., et al. (2002). The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. Journal of Clinical Investigation, 109, 1013–1020.
Serri, K., Reant, P., Lafitte, M., Berhouet, M., Le Bouffos, V., Roudaut, R., et al. (2006). Global and regional myocardial function quantification by two-dimensional strain: Application in hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 47, 1175–1181.
Spindler, M., Saupe, K. W., Christe, M. E., Sweeney, H. L., Seidman, C. E., Seidman, J. G., et al. (1998). Diastolic dysfunction and altered energetics in the alphaMHC403/+ mouse model of familial hypertrophic cardiomyopathy. Journal of Clinical Investigation, 101, 1775–1783.
Strijack, B., Ariyarajah, V., Soni, R., Jassal, D. S., Greenberg, C. R., McGregor, R., et al. (2008). Late gadolinium enhancement cardiovascular magnetic resonance in genotyped hypertrophic cardiomyopathy with normal phenotype. Journal of Cardiovascular Magnetic Resonance, 10, 58.
Sutherland, G. R., Di Salvo, G., Claus, P., D'Hooge, J., & Bijnens, B. (2004). Strain and strain rate imaging: A new clinical approach to quantifying regional myocardial function. Journal of the American Society of Echocardiography, 17, 788–802.
Tardiff, J. C. (2005). Sarcomeric proteins and familial hypertrophic cardiomyopathy: Linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Failure Reviews, 10, 237–248.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article is available at http://dx.doi.org/10.1007/s12265-013-9484-x.
Rights and permissions
About this article
Cite this article
Ho, C.Y. Hypertrophic Cardiomyopathy: Preclinical and Early Phenotype. J. of Cardiovasc. Trans. Res. 2, 462–470 (2009). https://doi.org/10.1007/s12265-009-9124-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12265-009-9124-7